Sulzer Cervical Fusion System Gains Panel Nod; Firm May Be First To Market
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Spine-Tech should perform a sensitivity analysis on existing data to make a stronger case that patients who dropped out of the study's control group did not bias conclusions in favor of the firm's BAK/C cervical interbody fusion system, FDA's Orthopedic and Rehabilitation Devices panel recommended.
You may also be interested in...
Sulzer Medica's BAK/C
FDA "approvable" letter for the cervical interbody fusion system is received March 19. The agency's Orthopedic and Rehabilitation Devices Panel unanimously recommended approval of a premarket approval application for the device Jan. 19 (1"The Gray Sheet" Jan. 22, 2001, p. 13). Sulzer estimates the cervical fusion market at approximately $160 mil. this year and annual growth of 19%. Upon final approval by FDA, the BAK/C will be the first cervical interbody fusion device to reach the U.S. market
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.